Navigation Links
Burn injuries take devastating toll on nation's children
Date:11/12/2007

The approach of winter season brings with it an increase in burn-related injuries to our nations children. Annually in the United States, fires and burns result in almost 4,000 deaths and more than 745,000 non-hospitalized injuries among all age groups.

A new study conducted by researchers at the Center for Injury Research and Policy at Nationwide Childrens Hospital, concludes that burn-associated injuries among children and adolescents in the U.S. may be a more significant public health concern than previously estimated. The study, published in the November issue of the Journal of Burn Care and Rehabilitation, estimates there are approximately 10,000 pediatric (18-years-old and younger) burn injuries annually in the U.S., resulting in almost $212 million in hospital inpatient charges.

Burns are a major source of pediatric death and disability and are associated with significant national healthcare resource utilization, said study senior author Gary Smith, MD, DrPH, director of the Center for Injury Research and Policy at Nationwide Childrens Hospital, and faculty member at The Ohio State University College of Medicine. Burns often require long periods of rehabilitation, multiple skin grafts and extensive physical therapy. Not only can burn-related injuries leave patients with lifelong physical and psychological disabilities, they often also result in significant burdens for the patients families and caregivers.

The study found that children 2-years-old or younger were more likely to be hospitalized for burns to their hands or wrists and from contact with hot liquids or objects, compared with children 3 to 17-years-old who were more likely to be burned by fire. Children 2 years of age and younger accounted for half of the children hospitalized for burns, and almost two-thirds of hospitalized children were male. The average length of hospital stay was 7 days with an average inpatient hospital charge of $21,800.

Findings from o
'/>"/>

Contact: Mary Ellen Fiorino
MaryEllen.Fiorino@NationwideChildrens.org
614-722-4595
Nationwide Children's Hospital
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New insights into common knee injuries
2. More Kids Are Suffering Sports Injuries
3. Injuries, Deaths Tied to Consumer Drugs Rise Sharply
4. OSHA Issues Draft Ergonomics Guidelines on Preventing Musculoskeletal Injuries in Shipyards
5. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
6. Smith & Nephew Endoscopys KINSA(R) RC Suture Anchor Designed for Secure Repair of Rotator Cuff Injuries
7. High school footballers wearing special helmets to monitor brain injuries
8. UT Southwestern investigating hypothermic technique in treating pediatric head injuries
9. Easter Seals Launches Program for Veterans Returning from Iraq and Afghanistan with Traumatic Brain Injuries
10. Americans Pessimistic View of Accident Prevention Poses Hurdle to Reducing Injuries, Survey Says
11. National study -- kids bike injuries are major public health concern
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 1The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 2The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 3Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 1Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 2Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 3Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 4Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 5AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 1AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 2AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 3AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 4